ANG Lifesciences India Ltd

ANG Lifesciences India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 18 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

ANG Lifesciences India Limited reported a net loss of ₹1.38 crores for Q1 FY27 (April-June 2026), narrowing from a ₹4.75 crores loss in the previous quarter. Despite a 25.47% quarter-on-quarter revenue increase to ₹23.50 crores, the Amritsar-based pharmaceutical company continues to grapple with persistent profitability challenges that have plagued operations for over three years. The stock surged 7.84% to ₹29.45 following the results announcement, though the micro-cap company's market capitalisation remains modest at ₹38.46 crores.

ANG Lifesciences India Ltd has demonstrated a notable improvement in its financial performance for the quarter ended March 2026, reversing a previously negative trend. The company’s revenue growth, margin expansion, and profitability metrics have all shown encouraging signs, signalling a potential shift in its operational trajectory despite ongoing market challenges.

ANG Lifesciences India Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 Jun 2023. However, the analysis and financial metrics discussed here reflect the company’s current position as of 27 May 2026, providing investors with the latest insights into its performance and outlook.

ANG Lifesciences India Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 Jun 2023. However, the analysis and financial metrics discussed here reflect the company’s current position as of 13 May 2026, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trends, and technical outlook.

ANG Lifesciences India Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 Jun 2023. However, the analysis and financial metrics discussed here reflect the company’s current position as of 28 April 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trend, and technical outlook.

ANG Lifesciences India Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 June 2023. However, the analysis and financial metrics discussed below reflect the company’s current position as of 16 April 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trend, and technical outlook.

For the seventh consecutive session, ANG Lifesciences India Ltd has closed lower, culminating in a fresh 52-week low of Rs 17.63 on 30 Mar 2026. This sustained decline has erased 16.85% of the stock’s value over the past week, signalling persistent selling pressure amid a challenging market backdrop.

For the sixth consecutive session, ANG Lifesciences India Ltd has closed lower, culminating in a fresh 52-week low of Rs 18.5 on 27 Mar 2026. This marks a 15.98% decline over this losing streak, underscoring persistent selling pressure amid broader market weakness.

ANG Lifesciences India Ltd’s stock price declined to a fresh 52-week low of Rs.19 on 25 March 2026, marking a significant milestone in the company’s ongoing downward trajectory. This new low comes amid a series of consecutive losses and reflects persistent challenges faced by the pharmaceutical and biotechnology firm.

For the fourth consecutive session, ANG Lifesciences India Ltd has closed lower, culminating in a fresh 52-week low of Rs 19.51 on 24 Mar 2026. This marks a significant 50.9% decline from its 52-week high of Rs 39.7, underscoring persistent selling pressure amid challenging fundamentals and market headwinds.

For the third consecutive session, ANG Lifesciences India Ltd has declined, culminating in a fresh 52-week low of Rs 21 on 23 Mar 2026. This drop comes amid a broader market downturn, but the stock’s underperformance is notably sharper than its sector peers.

ANG Lifesciences India Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 June 2023. However, the analysis and financial metrics presented here reflect the stock’s current position as of 19 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

ANG Lifesciences India Limited, a micro-cap pharmaceutical company with a market capitalisation of ₹33.00 crores, reported a quarterly net loss of ₹4.75 crores for Q3 FY26 ended December 2025, marking a 61.02% sequential deterioration from the previous quarter's loss of ₹2.95 crores. On a year-on-year basis, losses expanded 8.48% from ₹5.19 crores in Q3 FY25, as the company grapples with a sustained revenue contraction and negative operating margins.

ANG Lifesciences India Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 June 2023. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 07 February 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trend, and technical outlook.